|
CA2215905A1
(en)
|
1995-03-20 |
1996-09-26 |
Sumitomo Electric Industries, Ltd. |
Monoclonal antibody reacting specifically with fas ligand and process for producing the same
|
|
AU6091496A
(en)
*
|
1995-06-07 |
1996-12-30 |
Chiron Corporation |
Antibodies to fas antigen capable of inhibiting apoptosis
|
|
US6096312A
(en)
*
|
1995-06-30 |
2000-08-01 |
Mochida Pharmaceutical Co., Ltd. |
Agent for suppressing a reduction of CD4+ lymphocytes
|
|
JPH09124509A
(ja)
*
|
1995-10-27 |
1997-05-13 |
Sumitomo Electric Ind Ltd |
肝炎治療剤
|
|
DE19544333C2
(de)
*
|
1995-11-28 |
1998-12-10 |
Deutsches Krebsforsch |
Verfahren zur Beurteilung der Aktivität von Arzneistoffen
|
|
WO1997039722A2
(en)
*
|
1996-04-25 |
1997-10-30 |
T Cell Sciences, Inc. |
Method of isolating regulators of t cell activation
|
|
GB9703276D0
(en)
*
|
1997-02-17 |
1997-04-09 |
Screaton Gavin R |
Materials and methods relating to the protection of useful immune cells
|
|
EP1025242A1
(en)
*
|
1997-10-30 |
2000-08-09 |
Cornell Research Foundation, Inc. |
A method of inhibiting an immune response to a recombinant vector
|
|
EP1447093A1
(en)
|
2003-02-14 |
2004-08-18 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries
|
|
WO2004085479A2
(en)
|
2003-03-26 |
2004-10-07 |
Apogenix Gmbh |
Treatment of viral infections
|
|
US9309320B2
(en)
|
2006-12-28 |
2016-04-12 |
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts |
Neutralization of CD95 activity blocks invasion of glioblastoma cells in vivo
|
|
EP2310409A2
(en)
|
2008-06-17 |
2011-04-20 |
Apogenix GmbH |
Multimeric tnf receptors
|
|
CN102497886B
(zh)
*
|
2009-07-21 |
2016-01-20 |
玛丽皇后与斯特菲尔德学院 |
用于细胞内药物递送的Fas(Apo-1,CD95)靶向平台
|
|
JP6297552B2
(ja)
|
2012-07-18 |
2018-03-20 |
アポジェニックス アーゲー |
Mdsの治療のための、cd95シグナル伝達経路阻害剤
|
|
EP3076179A1
(en)
|
2015-03-30 |
2016-10-05 |
Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts |
Diagnosis and treatment of low grade gliomas
|
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
|
AU2018205234B2
(en)
|
2017-01-06 |
2024-09-19 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (TILs) with tumor necrosis factor receptor superfamily (TNFRSF) agonists and therapeutic combinations of TILs and TNFRSF agonists
|
|
ES3055314T3
(en)
|
2017-01-06 |
2026-02-11 |
Iovance Biotherapeutics Inc |
Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
|
|
WO2018209115A1
(en)
|
2017-05-10 |
2018-11-15 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
JP2021503885A
(ja)
|
2017-11-22 |
2021-02-15 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
末梢血からの末梢血リンパ球(pbl)の拡大培養
|
|
EP3724885A2
(en)
|
2017-12-15 |
2020-10-21 |
Iovance Biotherapeutics, Inc. |
Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
|
|
CA3090795A1
(en)
|
2018-02-13 |
2019-08-22 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
|
|
SG11202109331QA
(en)
|
2019-03-01 |
2021-09-29 |
Iovance Biotherapeutics Inc |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
CN114269370A
(zh)
|
2019-03-29 |
2022-04-01 |
迈斯特治疗公司 |
离体产生t细胞治疗剂的方法以及相关的组合物和方法
|
|
IL293350A
(en)
|
2019-11-27 |
2022-07-01 |
Myst Therapeutics Llc |
Method of producing tumor-reactive t cell composition using modulatory agents
|
|
EP4110799B1
(en)
|
2020-02-27 |
2024-11-06 |
Turnstone Biologics Corp. |
Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof
|
|
US20260124242A1
(en)
|
2022-11-04 |
2026-05-07 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
WO2026044087A1
(en)
|
2024-08-21 |
2026-02-26 |
Shape Therapeutics Inc. |
Increased cellular stability for aav production
|
|
WO2026073032A1
(en)
|
2024-09-27 |
2026-04-02 |
Shape Therapeutics Inc. |
Constructs for improved aav production
|